122 participants
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-30
- Start Date:
- 2018-04-03
- Completion:
- 2026-06-30
Conditions
- Neuroblastoma
Interventions
- BIOLOGICAL
No Results Yet